FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. (FHTX) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.23 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +23.7% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. is based in CAMBRIDGE, Mass.
Sector
Healthcare
Industry
Biotechnology